Cargando…
Repurposing the Medicines for Malaria Venture’s COVID Box to discover potent inhibitors of Toxoplasma gondii, and in vivo efficacy evaluation of almitrine bismesylate (MMV1804175) in chronically infected mice
Toxoplasmosis, caused by the obligate intracellular parasite Toxoplasma gondii, affects about one-third of the world’s population and can cause severe congenital, neurological and ocular issues. Current treatment options are limited, and there are no human vaccines available to prevent transmission....
Autores principales: | dos Santos, Bruna Ramos, Ramos, Amanda Bruno da Silva Bellini, de Menezes, Renata Priscila Barros, Scotti, Marcus Tullius, Colombo, Fábio Antônio, Marques, Marcos José, Reimão, Juliana Quero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328330/ https://www.ncbi.nlm.nih.gov/pubmed/37418497 http://dx.doi.org/10.1371/journal.pone.0288335 |
Ejemplares similares
-
Drug Repurposing Based on Protozoan Proteome: In Vitro Evaluation of In Silico Screened Compounds against Toxoplasma gondii
por: Cajazeiro, Débora Chaves, et al.
Publicado: (2022) -
Role of almitrine bismesylate in managing refractory hypoxemia in COVID19 acute respiratory distress syndrome
por: Nair, Abhijit S., et al.
Publicado: (2021) -
Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome
por: Cardinale, Michael, et al.
Publicado: (2020) -
MMV in partnership: the Eurartesim(®) experience
por: Ubben, David, et al.
Publicado: (2013) -
Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma gondii Growth
por: Dittmar, Ashley J., et al.
Publicado: (2016)